Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Randomized, Two-Way Crossover, Comparative Study to Evaluate the Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl Versus Placebo in Children With Chronic Traumatic Brain Injury|
- Improvement in Spasticity, Cognition and Daily Function [ Time Frame: 4 weeks ]
- Improvement in nighttime actigraphy sleep parameters [ Time Frame: 4 weeks ]
|Study Start Date:||December 2006|
|Study Completion Date:||May 2007|
Sublingual tizanidine, a novel test formulation of the known effective antispasticity agent, has been shown to have a unique pharmacokinetic profile [(i.e., nearly twice the bioavailability/AUC), but with little or no increase in peak plasma levels (Cmax), as compared to oral tizanidine (Zanaflex)]. When administered nightly to CP (Cerebral Palsy) patients to more effectively reduce the muscle spasms that disrupt sleep, it was shown to improve sleep efficiency, decrease sleep fragmentation and improve the sleep cycle. This improvement in night-time sleep was translated into a potential improvement in next-day functioning (improvement in next-day measures of spasticity and movement).
It is hypothesized that a similar type of improvement in sleep with consequent positive impact on next day improvement in spasticity, cognition and function, may also be manifest in a similar patient population, children with traumatic brain injury.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00287157
|Alyn Hospital Pediatric and Adolescent Rehabilitation Center|
|Jerusalem, Israel, 01090|
|Principal Investigator:||Ido Yatsiv, MD||Hadassah Medical Center, Ein Kerem, Jerusalem|